https://pharminent.com/lilly-beats-estimates-raises-sales-outlook-on-zepbound-and-mounjaro/ 2026-10-29T11:59:48Z Pharminent en Merck tops quarterly estimates and raises profit outlook on Keytruda 2026-10-29T11:45:45Z Blog https://pharminent.com/manufacturing-intelligence/manufacturing-intelligence-weekly-digest-october-28-2026/ 2026-10-28T23:58:44Z Pharminent en Manufacturing Intelligence • Weekly Digest • October 28, 2026 2026-10-28T23:58:44Z Blog https://pharminent.com/neuromarket-pulse/neuromarket-pulse-weekly-neuroscience-competitive-intelligence-october-28-2026/ 2026-10-28T23:58:13Z Pharminent en NeuroMarket Pulse • Weekly Neuroscience Competitive Intelligence • October 28, 2026 2026-10-28T23:58:13Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-october-28-2026/ 2026-10-28T15:16:48Z Pharminent en Strategic News Watch • October 28, 2026 2026-10-28T15:16:48Z Blog https://pharminent.com/lilly-says-retatrutide-beat-novos-ozempic-in-diabetes-study/ 2026-10-28T11:45:40Z Pharminent en Lilly says retatrutide beat Novo's Ozempic in diabetes study 2026-10-28T11:45:40Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-october-27-2026/ 2026-10-28T00:22:32Z Pharminent en Oncology Intelligence Digest • October 27, 2026 2026-10-28T00:22:32Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-october-27-2026/ 2026-10-27T14:48:16Z Pharminent en Strategic News Watch • October 27, 2026 2026-10-27T14:48:16Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-october-26-2026/ 2026-10-27T14:46:49Z Pharminent en Rare Disease & Gene Therapy Digest • October 26, 2026 2026-10-27T14:46:49Z Blog https://pharminent.com/fda-expands-pfizers-talzenna-xtandi-label-to-hormone-sensitive-prostate-cancer/ 2026-10-27T11:45:48Z Pharminent en FDA expands Pfizer's Talzenna-Xtandi label to hormone-sensitive prostate cancer 2026-10-27T11:45:48Z Blog